Bailard Inc. Purchases New Shares in Pediatrix Medical Group, Inc. $MD

Bailard Inc. acquired a new position in shares of Pediatrix Medical Group, Inc. (NYSE:MD) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 42,200 shares of the company’s stock, valued at approximately $707,000.

Other hedge funds have also bought and sold shares of the company. Allianz Asset Management GmbH grew its position in Pediatrix Medical Group by 159.1% in the 2nd quarter. Allianz Asset Management GmbH now owns 61,412 shares of the company’s stock valued at $881,000 after acquiring an additional 37,712 shares during the last quarter. Hsbc Holdings PLC grew its holdings in shares of Pediatrix Medical Group by 226.6% in the second quarter. Hsbc Holdings PLC now owns 111,997 shares of the company’s stock worth $1,591,000 after purchasing an additional 77,704 shares during the last quarter. Edgestream Partners L.P. purchased a new position in Pediatrix Medical Group in the 2nd quarter worth about $763,000. Wedge Capital Management L L P NC purchased a new position in Pediatrix Medical Group in the 3rd quarter worth about $2,315,000. Finally, Wakefield Asset Management LLLP purchased a new stake in Pediatrix Medical Group in the 2nd quarter valued at about $1,002,000. Institutional investors own 97.71% of the company’s stock.

Insiders Place Their Bets

In other Pediatrix Medical Group news, Director Laura A. Linynsky sold 10,000 shares of Pediatrix Medical Group stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $21.65, for a total value of $216,500.00. Following the transaction, the director directly owned 32,232 shares of the company’s stock, valued at approximately $697,822.80. The trade was a 23.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael A. Rucker sold 10,478 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of $23.00, for a total value of $240,994.00. Following the sale, the director owned 59,101 shares of the company’s stock, valued at approximately $1,359,323. This represents a 15.06% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 43,478 shares of company stock valued at $972,924. 0.90% of the stock is currently owned by insiders.

Pediatrix Medical Group Price Performance

Shares of MD stock opened at $21.50 on Friday. The stock’s 50-day moving average is $22.39 and its 200 day moving average is $18.42. Pediatrix Medical Group, Inc. has a 1-year low of $11.84 and a 1-year high of $24.99. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.83 and a quick ratio of 1.83. The company has a market cap of $1.85 billion, a P/E ratio of 11.31 and a beta of 0.73.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings results on Monday, November 3rd. The company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.46 by $0.21. Pediatrix Medical Group had a net margin of 8.44% and a return on equity of 20.45%. The business had revenue of $492.88 million during the quarter, compared to analyst estimates of $476.45 million. During the same period in the prior year, the firm posted $0.44 earnings per share. The company’s quarterly revenue was down 3.6% on a year-over-year basis. Research analysts predict that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MD has been the topic of a number of research reports. Truist Financial raised their target price on shares of Pediatrix Medical Group from $17.00 to $24.00 and gave the stock a “hold” rating in a research report on Monday, November 10th. UBS Group lifted their target price on Pediatrix Medical Group from $16.50 to $23.00 and gave the company a “neutral” rating in a research report on Wednesday, November 5th. Weiss Ratings reissued a “hold (c+)” rating on shares of Pediatrix Medical Group in a research report on Monday, December 29th. Zacks Research upgraded Pediatrix Medical Group from a “hold” rating to a “strong-buy” rating in a report on Friday, November 21st. Finally, Wall Street Zen upgraded shares of Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 4th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $21.00.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.